CanSino says vaccine demand down after China’s mass Covid infections
Pharma group hopes for approval of mRNA vaccine for booster shots。
中国结束清零政策时，康希诺正在推出一款吸入式疫苗。目前该公司在研发一款mRNA疫苗，以期用作加强针。
Chinese pharmaceutical group CanSino Biologics said demand for its Covid-19 vaccine was “dying down” in China after the abrupt end of the country’s tough zero-Covid policies, underscoring the challenges facing the sector in the largest remaining under-vaccinated market.
中国制药集团康希诺生物(CanSino Biologics)表示，在中国突然结束严格的清零政策后，其新冠疫苗在中国的需求正在“大幅下降”。此言突显出该行业在中国市场面临的挑战，在仅剩的新冠疫苗接种不足的市场中，中国是最大的一个。
CanSino was in the middle of rolling out an inhaled version of a coronavirus vaccine when China shed lockdown restrictions in early December. The vaccine had received emergency approval, adding to the existing dozen domestic vaccines serving the Chinese population.
当中国在去年12月初解除封锁限制时，康希诺正在推出一款吸入式新型冠状病毒疫苗。该疫苗已获得紧急批准，为现有十几种服务于中国人的国产疫苗又增加一种。
Yu Xuefeng, co-founder and chief executive of the Tianjin-based group, said it had rolled out “millions of doses” before the “surprise end of zero-Covid”. But Yu added that the campaign was outpaced by the virus, which infected an estimated 80 per cent of the population within weeks.
这家总部位于天津的集团的联合创始人兼首席执行官宇学峰表示，在“清零意外结束”之前，该公司已推出了“数百万剂疫苗”。但宇学峰补充说，其推广速度赶不上病毒传播速度，在几周内，估计80%的人口被感染。
